UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of bone and mineral research, ISSN 0884-0431, 01/2015, Volume 30, Issue 1, pp. 3 - 23
OSTEONECROSIS OF THE JAW | DIAGNOSIS | BISPHOSPHONATES | MANAGEMENT | RISK FACTORS | DENOSUMAB | IMAGING | TREATMENT | Treatment | Imaging | Osteonecrosis of the jaw | Diagnosis | Management | Denosumab | Bisphosphonates | Risk factors | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Humans | Osteoporosis - diagnosis | Osteoporosis - drug therapy | Mandible - diagnostic imaging | Monocytes - immunology | Cone-Beam Computed Tomography | Bisphosphonate-Associated Osteonecrosis of the Jaw - immunology | Mandible - immunology | Bacterial Infections - immunology | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnostic imaging | Osteoporosis - diagnostic imaging | Monocytes - pathology | Diphosphonates - therapeutic use | T-Lymphocytes - pathology | Diphosphonates - adverse effects | Macrophages - immunology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Osteoporosis - immunology | Macrophages - pathology | Risk Factors | Receptors, Antigen, T-Cell, gamma-delta - immunology | Consensus | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | T-Lymphocytes - immunology | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Care and treatment | Bacterial infections | Platelet-derived growth factor | Corticosteroids | Diagnostic imaging | Transplantation | T cells | Necrosis | Osteoporosis | Toiletries industry | Stem cells | Bones | Health aspects | Scanning devices | Index Medicus
Journal Article
Expert opinion on drug safety, ISSN 1474-0338, 07/2016, Volume 15, Issue 7, pp. 925 - 935
sunitinib | Bisphosphonate | everolimus | temsirolimus | aflibercept | Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) | bevacizumab | Osteonecrosis of the jaw (ONJ) | Medication-Related Osteonecrosis of the Jaw (MRONJ) | denosumab | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Jaw Diseases - diagnosis | Osteonecrosis - diagnosis | Risk Assessment - methods | Humans | Antineoplastic Agents - administration & dosage | Osteonecrosis - pathology | Molecular Targeted Therapy | Neoplasms - drug therapy | Jaw Diseases - chemically induced | Angiogenesis Inhibitors - administration & dosage | Jaw Diseases - pathology | Antineoplastic Agents - adverse effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Quality of Life | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Osteonecrosis - chemically induced | Angiogenesis Inhibitors - adverse effects | Index Medicus
Journal Article
British dental journal, ISSN 0007-0610, 04/2013, Volume 214, Issue 7, pp. 349 - 349
Journal Article
Journal of veterinary internal medicine, ISSN 0891-6640, 03/2019, Volume 33, Issue 2, pp. 862 - 867
hypercalcemia | osteomyelitis | pamidronate | aminobisphosphonate | alendronate | bisphosphonate‐related osteonecrosis of the jaw | bisphosphonate-related osteonecrosis of the jaw | Life Sciences & Biomedicine | Veterinary Sciences | Science & Technology | Cats | Cat Diseases - drug therapy | Oral Ulcer - etiology | Cat Diseases - chemically induced | Bisphosphonate-Associated Osteonecrosis of the Jaw - veterinary | Alendronate - therapeutic use | Alendronate - adverse effects | Animals | Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Diphosphonates - therapeutic use | Female | Hypercalcemia - drug therapy | Hypercalcemia - veterinary | Oral Ulcer - veterinary | Diphosphonates - adverse effects | Bones | Alendronate | Disodium pamidronate | Necrosis | Drugs | Jaw | Edema | Mucosa | Neutrophils | Osteonecrosis | Bisphosphonates | Hypercalcemia | Biomedical materials | Histopathology | Antibiotics | Biopsy | Bone density | SMALL ANIMAL | Case Report
Journal Article
Brain, behavior, and immunity, ISSN 0889-1591, 05/2010, Volume 24, Issue 4, pp. 564 - 568
Journal Article
Oral diseases, ISSN 1354-523X, 03/2018, Volume 24, Issue 1-2, pp. 52 - 56
bisphosphonate | osteonecrosis | surgical management | antiresorptives | bisphosphonate‐related osteonecrosis of the jaws | osteonecrosis of the jaws | bisphosphonate-related osteonecrosis of the jaws | Life Sciences & Biomedicine | Dentistry, Oral Surgery & Medicine | Science & Technology | Piezosurgery | Severity of Illness Index | Bone Density Conservation Agents - adverse effects | Humans | Laser Therapy | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Conservative Treatment | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Denosumab - adverse effects | Diphosphonates - adverse effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - surgery | Bones | Care and treatment | Surgery | Necrosis | Jaw | Clinical aspects | Osteonecrosis | Bisphosphonates | Maxillofacial surgery | Dentistry
Journal Article
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 01/2019, Volume 162, pp. 286 - 290
Osteonecrosis | Liquid chromatography | Bisphosphonates | Mass spectrometry | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Chemistry, Analytical | Life Sciences & Biomedicine | Science & Technology | Reproducibility of Results | Chromatography, High Pressure Liquid - methods | Bone Density Conservation Agents - adverse effects | Humans | Middle Aged | Male | Zoledronic Acid - metabolism | Tandem Mass Spectrometry | Spectrometry, Mass, Electrospray Ionization | Jaw - metabolism | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Female | Jaw - drug effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Zoledronic Acid - adverse effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - metabolism | Bone Density Conservation Agents - metabolism | Bisphosphonate-Associated Osteonecrosis of the Jaw - surgery | Osteoporosis | Diazo compounds | Usage | Phosphorus compounds | Analysis | Methods | Index Medicus
Journal Article
Biological & pharmaceutical bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 6, pp. 739 - 750
clodronate | bisphosphonate | osteonecrosis | inflammation | etidronate | Bisphosphonate | Inflammation | Osteonecrosis | Etidronate | Clodronate | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Analgesics - pharmacology | Analgesics - therapeutic use | Bone Density Conservation Agents - adverse effects | Humans | Bone Resorption - drug therapy | Bone Density Conservation Agents - therapeutic use | Bone Resorption - immunology | Denosumab - adverse effects | Bone Density Conservation Agents - pharmacology | Bisphosphonate-Associated Osteonecrosis of the Jaw - immunology | Animals | Nitrogen - chemistry | Analgesics - chemistry | Diphosphonates - chemistry | Interleukin-1 - immunology | Diphosphonates - therapeutic use | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Denosumab - pharmacology | Diphosphonates - adverse effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - drug therapy | Bisphosphonate-Associated Osteonecrosis of the Jaw - prevention & control | Diphosphonates - pharmacology | Analgesics - adverse effects | Bone Density Conservation Agents - chemistry | Phosphates | Jaw | Transportation | Clinical trials | Cytotoxicity | Infections | Tissues | Bisphosphonates | Bone resorption | Biomedical materials | Pain | Bones | Bacteria | Biocompatibility | Medical research | Cell walls | Nitrogen | Clodronic acid | Soft tissues | Side effects | Etidronic acid | Osteoclasts | Bone (long) | Transporter | Index Medicus
Journal Article